The global Inflammatory Bowel Disease (IBD) Treatment Market size
is expected to reach USD 22.4 billion by 2026, according to a new report by
Grand View Research, Inc., registering a 4.4% CAGR during the forecast period.
Increasing prevalence and incidence of Crohn’s disease and ulcerative colitis
is one of the major factors contributing to the market.
According to a study published in the NCBI
in 2019, the North America incidence of inflammatory bowel disease (IBD)
treatment is around 2.2 to 19.2 cases per 100,000 persons per year. It was also
published that around 238 per 100,000 population in U.S. were suffering from
ulcerative colitis. Furthermore, The Centers for Disease Control and Prevention
(CDC) estimates that in U.S., every year nearly 1-1.3 million people suffer
from inflammatory bowel disease.
In addition, involvement of regulatory
bodies for funding and designation is expected to propel the growth of the
market. For instance, the Crohn’s and Colitis Foundation offers grants and
fellowships for research on inflammatory bowel disease (includes Crohn’s disease
and ulcerative colitis).
Growing geriatric population is expected to
positively impact the overall market. According to an article published in 2018
in the United States Census Bureau, it is estimated that by 2035, the
population aged 65 years and above is expected to reach 78 million, whereas
children under the age of 18 might be around 76.7million.
Moreover, companies such as Johnson &
Johnson Services Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; and
AbbVie Inc. are majorly involved in product research and development and this
is also considered as one of the major driving factors for the market.
Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market
https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market
Further key
findings from the report suggest:
- The global inflammatory bowel disease treatment market is
anticipated to reach USD 22.4 billion by 2026, exhibiting a CAGR of 4.4%
from 2018 to 2026
- Crohn’s disease dominated the market by type in 2018 due to
increasing incidence of the disease. On the other hand, ulcerative colitis
was estimated to be the fastest growing segment owing to presence of
strong pipeline products for its treatment
- By route of administration, injectables dominated the IBD treatment
market in 2018 while oral was estimated to be the fastest growing segment
over the forecast period
- Aminosalicylic acid (ASAs) was considered to be the largest oral
segment in 2018 and JAK inhibitors to be the fastest growing segment
- In 2018, TNF-inhibitors dominated the injectables segment while
anti-integrins are estimated to be the fastest growing segment
- Hospital pharmacy was the largest segment in 2018 with a market
share of 36.6% and online pharmacy was anticipated to be the fastest owing
to the comfort, flexibility and convenience provided
- North America held the dominant share in 2018 owing to presence of
key companies in this region. Asia Pacific, on the other hand, was
estimated to be the fastest growing region
- Some of the key companies operating in this market are Johnson
& Johnson Services Inc.; Pfizer Inc.; Takeda Pharmaceutical Company
Limited; AbbVie Inc.; Celltrion Healthcare Co., Ltd.; CELGENE CORPORATION;
COSMO PHARMACEUTICALS; Innovate Biopharmaceuticals; UCB S.A.; and Gilead
Sciences.
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
No comments:
Post a Comment